RBF Symposium

February 2, 2017 (Thursday)
9:30 hrs	Welcome Address Shri. Pankaj R. Patel Chief Patron The Ramanbhai Foundation 8th International Symposium
09.40 hrs	Lighting of the lamp
09.45 hrs	Opening remarks by Guest of Honour Dr. Richard DiMarchi Standiford H. Cox Distinguished Professor of Chemistry, Linda & Jack Gill Chair in Biomolecular Sciences, Indiana University
09.55 hrs	Introduction to the keynote speaker Dr. Sharvil P. Patel Deputy Managing Director Zydus Cadila
10.00 hrs		“ The Problem of Reproducibility in Biomedical Research” Jeff Flier, M.D. Dean of the Faculty of Medicine, Harvard Medical School, Harvard University
10.45	Q & A session
11.00 hrs	Vote of Thanks Mr. Ganesh Nayak COO & Executive Director Zydus Cadila
11.30	*Poster and Exhibition Session Inauguration* *Dr. Sharvil P. Patel* Deputy Managing Director Zydus Cadila
12:30 hrs	Lunch
Session I : Gastrointestinal and Liver Diseases
Chairpersons: Charles F. Burant, MD, Ph.D., Professor of Metabolism, The Burant Lab,vUniversity of Michigan Medical School Dr. S.K.Sarin, MD, DM, Senior Professor and Head, Hepatology, Director, Institute of Liver and Biliary Sciences (ILBS), &vWHO CC on Viral Hepatitis and Liver Diseases, New Delhi Dr Ajay Duseja, Department of Hepatology, PGIMER, Chandigarh
14:00 hrs		“Molecular Mediators of NAFLD” Jay Horton, MD Distinguished Chair in Human Nutrition, The University of Texas Southwestern Medical Center The University of Texas Southwestern Medical Center
14:30 hrs		“Specificity Matters –Musings on (somewhat unconventional) development of a targeted immunomodulatory biologic” Asit Parikh, MD, Ph.D Head of GI Therapeutic Area Unit, Takeda Pharmaceuticals Takeda Pharmaceuticals
15:00 hrs		"NASH in India: Perspectives and Prospects for management" Dr. S.K.Sarin, MD, DM Senior Professor and Head, Hepatology, Director, Institute of Liver and Biliary Sciences (ILBS), & WHO CC on Viral Hepatitis and Liver Diseases, New Delhi
15:30 hrs	Tea-Break
16:00 hrs		“Non-alcoholic steatohepatitis modulation by novel FXR & PPAR agonists” Bart Staels, Ph.D. Director UMR INSERM 1011, Professor at the Faculty of Pharmacy, Université Lille 2, France
16:30 hrs		“Hepatocyte PPARα is protective against NAFLD in neonate and adult mice" Walter Wahli, Ph.D Professor of Metabolic Disease, Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore
17:00 hrs		“Translating scientific discovery into a cure for NASH” Arun Sanyal, MD Professor of Medicine, Physiology and Molecular Pathology Virginia Commonwealth University Virginia Commonwealth University
17:30 hrs	Wrap-up

February 3, 2017 (Friday)
Session II : Cancer Therapeutics
09:15 hrs	Introduction
Chairpersons: Kapil Dhingra, MD; Retired Vice President, Roche, Director, KAPital Consulting LLC Phil Dawson, Ph.D., Associate Dean of Graduate Studies, Department of Chemistry California, Campus, The Scripps Research Institute
09.30 hrs		“Enabling personalized medicine in oncology: Current status and perspectives on the future” Kapil Dhingra, MD Retired Vice President, Roche, Director, KAPital Consulting LLC
10:00 hrs		“T-cell engineering for Cancer Application” Martin Pule, M.D. Founder & Chief Scientific Officer Autolus Limited
10:30 hrs		“ZYTP1 - a novel PARP inhibitor for management of solid tumors” Mukul Jain, Ph. D. Senior V P, Pharmacology & Toxicology Zydus Research Center
11:00 hrs	Tea-Break
11:30 hrs		“Discovery of New Protein Drug Targets by Comprehensively Screening the Extracellular Proteome” Lewis T. "Rusty" Williams, M.D., Ph.D. Founder, President and CEO, Five Prime Therapeutics, Inc.
12:00 hrs		“Mouse Models for Pharmacogenomic Discovery” Karen Reue, Ph.D. Professor, Human Genetics, Department of Human Genetics, David Geffen School of Medicine, University of California, Los Angeles
12:30 hrs	Lunch & Poster Sessions
Session III : Anti-infectives & Public Health
Chairpersons: Bikash Medhi, MBBS,MD(AIIMS),MAMS,FIMSA Professor, Department of Pharmacology, PGIMER, Chandigarh Reinhard Glueck, Ph.D; Chief Scientific Officer Zydus-VTC
14:00 hrs		“Public-Private Partnerships to Accelerate Innovation in Product Development” Rajeev Venkayya, MD President of Global Vaccine Business Unit, Takeda Pharmaceuticals
14:30 hrs		“Developing next-generation malaria medicines to address drug resistance and increase the operational feasibility of malaria elimination efforts” Jörg Möhrle, Ph.D. Vice President, Head of Translational Medicine, Research & Development, Medicines for Malaria Venture
15:00 hrs	Tea-Break
15:30 hrs		“The Discovery and Development of New Antivirals” Manoj Desai, Ph.D. Vice President, Medicinal Chemistry Gilead Sciences
16:00 hrs		“Opportunities and Challenges in the Vaccine Industry" Rahul Singhvi, Sc.D. Chief Operating Officer, Takeda Vaccines
16:30 hrs	Panel Discussion “Is there more integration between cancer, viral disease and the microbiome?” Jeff Flier, M.D., HMS Dean (2007-16), Harvard Medical School, Richard DiMarchi, Ph.D., Standiford H. Cox Distinguished Professor of Chemistry, Linda & Jack Gill Chair in Biomolecular Sciences, Indiana University Rajeev Venkayya, MD, President of Global Vaccine Business Unit, Takeda Pharmaceuticals Kapil Dhingra, MD, Retired Vice President, Roche, Director, KAPital Consulting LLC Manoj Desai, Ph.D., Vice President, Medicinal Chemistry, Gilead Sciences Arun Sanyal, MD, Professor of Medicine, Physiology and Molecular Pathology, Virginia Commonwealth University
17:30 hrs	Wrap-up

February 4, 2017 (Saturday)
Session IV : Cardio-metabolic Diseases
09.15 hrs	Introduction
Chairpersons: Jeff Flier, M.D.; Dean of the Faculty of Medicine, Harvard Medical School, Harvard University Jay Horton, MD Distinguished Chair in Human Nutrition, The University of Texas Southwestern Medical Center
09.30 hrs		“FGF21:physiology and therapeutic potential” Terry Flier, MD Professor of Medicine, Harvard Medical School Division of Endocrinology, Beth Israel Deaconess Medical Center
10:00 hrs		“Evolving mechanisms and continued challenges of the FGF-21 pathway as a therapeutic target” Saswata Talukdar, Ph.D. Director and Leader of CardioMetabolic Disease, Early Discovery group, Merck Research Laboratories
10:30 hrs		“Metabolism and metabolic aging” Charles F. Burant, MD, Ph.D. Professor of Metabolism, The Burant Lab, University of Michigan Medical School
11:00 hrs		“Melanocortins: From Pharmacology to Pharmacotherapy” Roger Cone, Ph.D. Mary Sue Coleman Director, Life Sciences Institute Professor of Molecular and Integrative Physiology University of Michigan
11:30 hrs	Lunch & Poster
Session V : Chemical Biotechnology
Chairpersons: Lewis T. "Rusty" Williams, M.D., Ph.D., Founder, President and CEO, Five Prime Therapeutics, Inc. Manoj Desai, Ph.D., Vice President, Medicinal Chemistry, Gilead Sciences
14:00 hrs		“Plants as bio-factories for producing peptide-based pharmaceuticals” David Craik, Ph.D. Group Leader, Chemistry and Structural Biology Division, The University of Queensland
14:30 hrs		“Making connections in peptide chemistry” Phil Dawson, Ph.D. Associate Dean of Graduate Studies, Department of Chemistry California Campus, The Scripps Research Institute
15:00 hrs		“High productive cell-lines, ADC process development and challenges” Palani Palaniappan, Ph.D. Vice President & Head, Biologics & New Modalities Development, Takeda Pharmaceuticals
15:30 hrs		“Chemical Biotechnology Applied to Metabolic Diseases” Richard DiMarchi, Ph.D. Standiford H. Cox Distinguished Professor of Chemistry, Linda & Jack Gill Chair in Biomolecular Sciences, Indiana University
16:00 hrs	Best Poster Awards Oral Poster Presentation 1 (10 min) Oral Poster Presentation 2 (10 min) Oral Poster Presentation 3 (10 min)
16:30 hrs	Closing Comments Dr. Sharvil P. Patel Deputy Managing Director Zydus Cadila